63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details


臨床試験数 : 391 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05338190
(ClinicalTrials.gov)
June 1, 202221/3/2022Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaA Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition to Rituximab in Adult Patients With Persistent or Chronic Immune Thrombocytopenia (ITP)Primary Immune Thrombocytopenia (ITP)Drug: Combination of Rituximab with subcutaneous belimumab;Drug: Combination of Rituximab with subcutaneous placeboAssistance Publique - Hôpitaux de ParisGlaxoSmithKlineNot yet recruiting18 YearsN/AAll132Phase 3NULL
2ChiCTR2200058433
2022-04-112022-04-09Belimumab in combination with cyclosporine for corticosteroid-refractory primary immune thrombocytopenia in adultsEfficacy and safety of belliumab in combination with cyclosporine in adults with persistent or chronic corticosteroid-refractory primary immune thrombocytopenia: a single-arm, open, multicenter clinical study Primary immune thrombocytopeniaGroup 1:belimumab and cyclosporine;The Second Affiliated Hospital of Kunming Medical UniversityNULLPendingBothGroup 1:37;China